secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2026-04-02T23:59:59+00:00
Accession:  0001628280-26-023196
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 2.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion closes $75M acquisition of Corstasis, adds Enbumyst nasal spray
------------------------------------------------------------------------

- Closed acquisition of Corstasis Therapeutics for $75M cash upfront; up to $180M in milestones and royalties.
- Acquired Enbumyst (bumetanide nasal spray), first FDA-approved nasal spray loop diuretic for edema.
- Entered $25M term loan amendment and $50M royalty sale to Athyrium to partially finance the deal.
- Enbumyst approved Sept 2025; Esperion plans commercial infrastructure to drive adoption.
- Acquisition supports Vision 2040, diversifies cardiometabolic portfolio, expected revenue growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828026023196/0001628280-26-023196-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828026023196/espr-20260402.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-023196

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer